Article
BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database.
Journal of the National Cancer Institute - 1 Oct 2021
Cohen Romain, Liu Heshan, Fiskum Jack, Adams Richard, Chibaudel Benoist, Maughan Timothy S, Van Cutsem Eric, Venook Alan, Douillard Jean-Yves, Heinemann Volker, Ja Punt Cornelis, Falcone Alfredo, Bokemeyer Carsten, Kaplan Richard, Lenz Heinz-Josef, Koopman Miriam, Yoshino Takayuki, Zalcberg John, Grothey Alex, de Gramont Aimery, Shi Qian, André Thierry
Abstract excerpt
BACKGROUND: First-line therapeutic strategies for patients with BRAFV600E-mutated (BRAFmt) metastatic colorectal cancer (mCRC) mainly rely on subgroup analyses from randomized controlled trials (RCTs). We aimed to assess the prognostic and predictive impact of BRAFmt on the efficacy of targeted therapies with first-line chemotherapy. METHODS: Individual patient data from first-line RCTs with BRAF and KRAS status...
Topics
- Colonic Neoplasms
- Colorectal Neoplasms
- Humans
- Mutation
- Proto-Oncogene Proteins B-raf
- Proto-Oncogene Proteins p21(ras)
- Randomized Controlled Trials as Topic
- Rectal Neoplasms